INT249117

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2008
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.22
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (Abl1, Bcr) cytosol (Abl1, Bcr) kinase activity (Abl1, Bcr)
mitochondrion (Abl1) intracellular (Bcr) enzyme binding (Bcr)
Abl1 (Mus musculus)
Bcr (Mus musculus)
Abl1 - E255K (1) Abl1 - T312I (1)
Pain Link Frequency Relevance Heat
Potency 21 99.12 Very High Very High Very High
Central nervous system 5 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Piles 1 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
Bioavailability 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Death 7 99.08 Very High Very High Very High
Myeloid Leukemia 178 98.04 Very High Very High Very High
Toxicity 8 97.84 Very High Very High Very High
Disease Progression 19 96.56 Very High Very High Very High
Disease 26 89.72 High High
Blast Crisis 32 84.04 Quite High
Thrombocytopenia 15 61.04 Quite High
Pleural Effusion 7 59.28 Quite High
Anaemia 1 57.08 Quite High
Neutropenia 6 54.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The ability to bind both active and inactive conformations of BCR-ABL may explain its potent activity against most of the known imatinib-resistant kinase domain mutations, with the exception of T315I [33].
ABL Binding (bind) of BCR
1) Confidence 0.36 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2567340 Disease Relevance 0.52 Pain Relevance 0.04
The increased potency of dasatinib, combined with its ability to bind multiple conformation of BCR-ABL, produces significant efficacy in patients with CML and Ph+ ALL.
ABL Binding (bind) of BCR associated with myeloid leukemia and potency
2) Confidence 0.36 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2567340 Disease Relevance 0.42 Pain Relevance 0.05
Such mutations inhibit the ability of imatinib to bind to BCR-ABL by corrupting the binding sites or preventing the kinase domain from assuming the inactive conformation required for imatinib binding [11].
ABL Neg (inhibit) Binding (bind) of BCR
3) Confidence 0.36 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2567340 Disease Relevance 0.32 Pain Relevance 0
Patients with BCR-ABL mutations E255K, T312I and F486S did not respond to dasatinib.
ABL (E255K, F486S, T312I) Binding (Patients) of BCR
4) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697539 Disease Relevance 0.97 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox